Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 53, Issue 4, 2009, Pages 543-550

  Galderisi, Faith ^a   Stork, Linda ^a   Li, Ju ^b   Mori, Motomi ^c   Mongoue Tchokote, Solange ^c   Huang, James ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Chemosensitivity assay; Childhood; Flow cytometry; In vitro drug resistance; Response to induction

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; LEUKEMIA RELAPSE; LYMPHOBLAST; MALE; MONONUCLEAR CELL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; BONE MARROW; DRUG RESISTANCE; DRUG SCREENING; INFANT; KARYOTYPING; METHODOLOGY; PATHOLOGY; RECURRENT DISEASE;

ADOLESCENT; ADULT; BONE MARROW; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT; KARYOTYPING; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE;

EID: 69849091837     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22119     Document Type: Article

References (48)

1. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1998;92:1838.
2. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995;345:143-148.
3. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52-58. (Pubitemid 35177428)
4. de Haas V, Breunis WB, Verhagen OJ, et al. Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse. Blood 2000;96:1619-1620.
5. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after one week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86:1292-1295.
6. Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990;18:273-279. (Pubitemid 20219917)
7. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review. Cancer 1997;80:1717-1726. (Pubitemid 27475928)
8. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-2233.
9. Lilleyman JS, Gibson BE, Stevens RF, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: Clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 1997;97:603-606.
10. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. J Clin Oncol 1989;7:1807-1815. (Pubitemid 20014327)
11. Miller DR, Leikin S, Albo V, et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from Childrens Cancer Study Group. Cancer 1983;51:1041-1049.
12. Panzer-Grümayer ER, Schneider M, Panzer S, et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000;95:790-794. (Pubitemid 30062697)
13. Riehm H, Reiter A, Schrappe M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987;199:151-160. (Pubitemid 17079852)
14. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Children's Cancer Group. J Clin Oncol 1996;14:389-398. (Pubitemid 26050999)
15. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008;111:5477-5485.
16. Pieters R, Klumper E, Kaspers GJ, et al. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol 1997;25:11-26. (Pubitemid 27138046)
17. Pappenheimer A. Experimental studies upon lymphocytes: I. The reactions of lymphocytes under various experimental conditions. J Exp Med 1917;25:633-650.
18. Bellamy WT. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 1992;44:690-708.
19. Hoffman RM. In vitro assays for chemotherapy sensitivity. Crit Rev Oncol Hematol 1993;15:99-111.
20. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:3262-3268. (Pubitemid 46606259)
21. Frost BM, Nygren P, Gustafsson G, et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003;122:376-385. (Pubitemid 36951621)
22. Hongo T, Yajima S, Sakuri M, et al. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997;89:2959-2965.
23. Janka-Schaub GE, Harms DO, den Boer ML, et al. In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Padiatr 1999;211:233-238.
24. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723-2729.
25. De Haas V, Kaspers GJ, Oosten L, et al. Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia? Br J Haematol 2002;118:1190-1191.
26. Lönnerholm G, Thörn I, Sundström C, et al. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia. Leuk Res 2009;33:46-53.
27. Pieters R, Huismans DR, Leyva A, et al. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 1988;41:323-332. (Pubitemid 18198023)
28. Hasper HJ, Weghorst RM, Richel DJ, et al. A new four-color flow cytometric assay to detect apoptosis in lymphocyte subsets of cultured peripheral blood cells. Cytometry 2000;40:167-171.
29. Savas ,an S, Buck S, Ozdemir O, et al. Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia. Leuk Lymphoma 2005;46:833-840.
30. Wuchter C, Ruppert V, Schrappe M, et al. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood 2002;99:4109-4115.
31. Zhong Y, Bakke AC, Fan G, et al. Drug resistance in B-cell chronic lymphocytic leukemia: Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay. Cytometry B Clin Cytom 2007;72:189-195. (Pubitemid 46676751)
32. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24. (Pubitemid 26019992)
33. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007;109:926-935.
34. Nygren P, Kristensen J, Jonsson B, et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992;6:1121-1128.
35. Rosner B. Fundamentals of biostatistics. Massachusetts: Duxbury Press; 2006. 716 p.
36. Kaspers GJ, Pieters R, Van Zantwijk CH, et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood 1998;92:259-266. (Pubitemid 28303201)
37. Schmiegelow K, Nyvold C, Seyfarth J, et al. Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia 2001;15:1066-1071. (Pubitemid 32717276)
38. Riehm H, Reiter A, Schrappe M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987;199:151-160. (Pubitemid 17079852)
39. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006. (Pubitemid 30180646)
40. Bloomfield CD, Secker-Walker LM, Goldman AI, et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet 1989;40:171-185. (Pubitemid 19235687)
41. Heerema NA, Nachman JB, Sather HN, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 1999;94:4036-4045.
42. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990;76:1449-1463. (Pubitemid 20364007)
43. Takahashi Y, Horibe K, Kiyoi H, et al. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998;20:190-195. (Pubitemid 28280893)
44. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21:6-12. (Pubitemid 29131987)
45. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000;96:1094-1099. (Pubitemid 30616878)
46. Stams WA, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005;105:4223-4225. (Pubitemid 40720766)
47. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10:331-342. (Pubitemid 44512194)
48. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756-3762.